Table 1 Patient baseline characteristics and demographics
radiochemotherapy | radioimmunotherapy | TPF induction | ||
|---|---|---|---|---|
site | pts, (%) | |||
hypopharynx | 17 (44.7) | 3 (7.9) | 5 (31.3) | |
oropharynx | 7 (18.4) | 6 (15.8) | 3 (18.8) | |
base of tongur | 5 (13.2) | 4 (10.5) | 1 (6.3) | |
oral cavity | 4 (10.5) | 12 (31.6) | 1 (6.3) | |
oro-/hypopharynx | 3 (7.9) | 5 (13.2) | 3 (18.8) | |
larynx | 1 (2.6) | 7 (18.4) | 1 (6.3) | |
oropharynx+hypopharynx | 1 (2.6) | 1 (6.3) | ||
lip | 1 (2.6) | |||
stage | T1 | 1 (2.6) | 6 (15.8) | |
T2 | 3 (7.9) | 6 (15.8) | 1 (6.3) | |
T3 | 4 (10.5) | 4 (10.5) | 2 (12.5) | |
T4 | 30 (78.9) | 22 (57.9) | 13 (81.3) | |
N0 | 3 (7.9) | 10 (26.3) | 1 (6.3) | |
N1 | 2 (5.3) | 4 (10.5) | 2 (12.5) | |
N2a | 3 (7.9) | |||
N2b | 5 (13.2) | 6 (15.8) | 4 (25) | |
N2c | 23 (60.5) | 15 (39.5) | 8 (50) | |
N3 | 4 (10.5) | 1 (6.3) | ||
pN2b | 1 (2.6) | |||
M1 | 2 (5.3) | 4 (10.5) | 0 | |
primary treatment | 35 (92.1) | 26 (68.4) | 15 (93.8) | |
local relapse | 3 (7.9) | 12 (31.6) | 1 (6.3) | |
seconday tumours | 2 (5.3) | 2 (5.3) | 2 (12.5) | |
Total | 38 | 38 | 16 | |
age [a] | median | 61.1 | 71.4 | 60.3 |
range | 17 - 74 | 50 - 85 | 17 - 68 | |
p < 0.001 | p < 0.001 |